お知らせ • Feb 24
Intellego Technologies AB Announces Board Appointments Intellego Technologies AB at its EGM held on 23 February 2026, resolved to elect Fredrik Olsson as a new board member and chairman of the board, as well as Anders Ermén, Mats Geijer and David Pastrana as new ordinary members of the board of directors. Fredrik Olsson, born in 1962, is an entrepreneur and investor with a special interest in growth companies in the Life Science sector. Fredrik has extensive experience of board work in listed companies, corporate governance and ownership-related issues. Fredrik Olsson is a member of the board of directors of Enorama Pharma AB (publ) and chairman of the company's nomination committee. Fredrik is also a board member of ASA des Palus de St Germain de la Rivière and CEO of Château Baulos la Rivière SAS. Anders Ermén, born in 1963, has run his own business since 1996 with a focus on accounting, business development and management. Anders has over 20 years of experience from the music, media and pharmaceutical industries, with a particular focus on accounting, taxation, internal control, financing and contract negotiations. Anders has extensive experience of board work in both listed and unlisted companies and has previously been chairman of the board of directors of Guard Therapeutics AB (publ), Enorama Pharma AB (publ), Enorama Inc. (USA) and a board member of Xintela AB (publ). Anders is also a board member of Ermén Produktion & Redovisning AB. Mats Geijer, born 1977, is a legal professional with 25 years of experience with background in shipping, insurance and litigation. Mats possesses special expertise in legal and regulatory challenges in connection with companies in turnaround, special-sits and disputes. Mats is also a board member of Aktiebolaget Fastator (publ), Park Capital AB and is currently Head of Nordics at Deminor Litigation Funding. Mats has published several articles related to publicly listed companies in disputes and is often engaged as speaker at conferences on this topic. David Pastrana, born in 1976, MBA from INSEAD, has more than 15 years of experience as President and CEO, and was previously CEO of Inditex USA. David is currently Managing Partner of Founders Capital, a differentiated Private Equity Firm, and a member of the board of directors of TSM. David has solid international leadership experience from large, complex organizations with a strong commercial focus and a proven ability to drive structured growth, operational efficiency and change management. David holds 139,261 shares in the Company. お知らせ • Jan 02
Hai Solutions Receives Fda Approval for Qikcap Intellego Technologies AB (publ) announced that the product QIKcap, owned by its partner company HAI Solutions (HAIS), has received approval from the U.S. Food and Drug Administration (FDA). The approval means that QIKcap may now be marketed and used within the U.S. healthcare system. QIKcap is based on HAI Solutions' patented technology, in which Intellego's photochromic indicator technology constitutes an integrated and essential part of the now approved product. Intellego holds an ownership interest of approximately 10.5% in HAIS and, in addition, has exclusive rights to sell QIKcap in the Chinese market. Intellego is also entitled to license revenues from global sales of the product. QIKcap is a single-use cap for intravenous access points, primarily catheters. The product combines a photochromic dosimeter and an optical lens to verify UVC exposure, with the aim of reducing the risk of intravenous contamination and bloodstream infections. お知らせ • Nov 22
Intellego Technologies AB Announces CEO Changes The board of directors of Intellego Technologies AB announced the appointment of Jacob Laurin, a board member of the company, as interim CEO, effective November 21, 2025. Claes Lindahl will step down from his role as CEO pending an investigation by the Swedish Economic Crime Authority (Ekobrottsmyndigheten). New Risk • Nov 18
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). High level of non-cash earnings (56% accrual ratio). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).